Last reviewed · How we verify
NCT03917966
The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC
Status unknown
Phase 2
Last updated 4 March 2022
What this trial tests
Phase 2 trial testing SHR-1210+docetaxel+nedaplatin in Locally Advanced Esophageal Squamous Cell Carcinoma in 80 participants. Status unknown.
Timeline
7 April 2020
Primary endpoint
7 October 2023
7 October 2023
7 October 2024
Quick facts
| Lead sponsor | The First Affiliated Hospital of Zhengzhou University |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 7 April 2020 |
| Primary completion | 7 October 2023 |
| Estimated completion | 7 October 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- SHR-1210+docetaxel+nedaplatin — full drug profile →
- SHR-1210+Apatinib
Conditions studied
- Locally Advanced Esophageal Squamous Cell Carcinoma — all drugs for Locally Advanced Esophageal Squamous Cell Carcinoma →
Sponsor
The First Affiliated Hospital of Zhengzhou University
Who can join
Adults 18 to 80, any sex, with Locally Advanced Esophageal Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to observe and evaluate the efficacy and safety of SHR-1210 combined with preoperative chemotherapy or Apatinib for locally advanced esophageal squamous cell carcinoma
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer: A Systematic Review and Meta-analysis.
Ge F, Huo Z, Cai X, Hu Q, et al · · 2022 · cited 94× · PMID 36322089 · DOI 10.1001/jamanetworkopen.2022.39778 -
Neoadjuvant immunotherapy for resectable esophageal cancer: A review.
Li Q, Liu T, Ding Z. · · 2022 · cited 43× · PMID 36569908 · DOI 10.3389/fimmu.2022.1051841 -
Recent Advances in Combination of Immunotherapy and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
Wang R, Liu S, Chen B, Xi M. · · 2022 · cited 35× · PMID 36291954 · DOI 10.3390/cancers14205168 -
The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer.
Yang H, Wang K, Wang T, Li M, et al · · 2020 · cited 35× · PMID 32195194 · DOI 10.3389/fonc.2020.00300 -
Immunotherapy for Esophageal Cancer: State-of-the Art in 2021.
Teixeira Farinha H, Digklia A, Schizas D, Demartines N, et al · · 2022 · cited 33× · PMID 35158822 · DOI 10.3390/cancers14030554 -
Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis.
Liu Y, Bao Y, Yang X, Sun S, et al · · 2023 · cited 24× · PMID 36761760 · DOI 10.3389/fimmu.2023.1117448 -
Treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy.
Yan Y, Feng X, Li C, Lerut T, et al · · 2022 · cited 17× · PMID 36525602 · DOI 10.1097/cm9.0000000000002371 -
Evaluation of neoadjuvant immunotherapy and traditional neoadjuvant therapy for resectable esophageal cancer: a systematic review and single-arm and network meta-analysis.
Wang H, Song C, Zhao X, Deng W, et al · · 2023 · cited 15× · PMID 37251393 · DOI 10.3389/fimmu.2023.1170569
Verify or expand the search:
- PubMed search for NCT03917966
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Locally Advanced Esophageal Squamous Cell Carcinoma
Currently open trials in the same condition.
- NCT06356688 — A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as · Phase 2 · recruiting
- NCT06843889 — A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squam · Phase 2 · recruiting
- NCT06342167 — Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carc · Phase 2 · active not recruiting
- NCT06187597 — Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) · Phase 2 · recruiting
- NCT06907602 — Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma · Phase 2, PHASE3 · recruiting
Other The First Affiliated Hospital of Zhengzhou University trials
Trials by the same sponsor.
- NCT07501962 — Effect of Intraluminal Administration of Menthol Solution During Colonoscopy on Colonic Spasm and Adenoma Detection Rate · NA · not yet recruiting
- NCT07501975 — Effect of a Novel Colonoscopic Lavage Solution on Colonoscopy Quality · NA · not yet recruiting
- NCT07454954 — The Effect of Blood Flow Restriction Training Combined With Transcranial Magnetic Stimulation on Limb Function in Hemipl · NA · not yet recruiting
- NCT05114941 — Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome · NA · not yet recruiting
- NCT07314619 — Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combi · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03917966 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Zhengzhou University
- Last refreshed: 4 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03917966.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing